cleome

by | Dec 1, 2017

Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.[1][2] Tabalumab was developed by Eli Lilly and Company.

A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013.[3] In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.[4]

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab" (PDF). American Medical Association.
  2. ^ "BAFF Antibody: Tabalumab, LY2127399". Lilly USA, LLC. Archived from the original on 12 August 2013.
  3. ^ "Press Release Archive - Press Release Archives".
  4. ^ "Lilly Halts Tabalumab Development for Lupus". 2 October 2014.

Now dropped by Lilly due to lack of efficacy.